AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases.
The company is best known for its work on antibodies to SARS-CoV2:
- New preclinical data show that LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern
- LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting effectiveness against emerging variants
- LY-CoV1404 neutralizes authentic SARS-CoV-2 with high potency in vitro
- LY-CoV1404 enters clinical trials as part of Lilly’s BLAZE-4 study in patients with mild-to-moderate COVID-19 illness